← Leaderboards
Thomas Joseph Hannan
Fimbrion Therapeutics, Inc.
$6,586,896
Attributed
$7,036,896
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,036,896 · 8
By mechanism
R44$4,618,884 · 2
R43$2,062,070 · 5
K08$355,942 · 1
Top collaborators
- Laurel Mcgrane2 shared
- Nicholas Jentsch1 shared
Most similar at Fimbrion Therapeutics, Inc.
Same institution · by research overlap
- Laurel McGrane$750,000
- Nicholas Jentsch$150,000
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionMouse ModelResistanceAcuteBacteriaPrevalenceIn VivoDrug KineticsLeadPropertyAntibioticsMetabolicIn VitroPharmaceutical PreparationsSmall MoleculeCellsToxic EffectAnimal ModelSeriesMortalityMycobacterium TuberculosisAntibiotic ResistanceAntimicrobial ResistanceChronic
Grant awards (15)
Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria$300,001
R43 · FY2025 · AI · contact PI
Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis$300,000
R43 · FY2025 · AI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$994,977
R44 · FY2024 · AI · contact PI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis$300,000
R43 · FY2024 · AI · contact PI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$997,875
R44 · FY2023 · AI · contact PI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis$300,000
R43 · FY2023 · AI · contact PI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$1,000,000
R44 · FY2022 · AI · contact PI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$293,050
R43 · FY2021 · AI · contact PI
Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis$300,000
R43 · FY2020 · AI · contact PI
Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs$724,797
R44 · FY2018 · AI · contact PI
Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs$901,235
R44 · FY2017 · AI · contact PI
Anti-virulence FimH inhibitors for the treatment and prevention of UTIs$269,019
R43 · FY2015 · AI · contact PI
Mucosal Immune Checkpoints in Chronic Bacterial Cystitis$121,369
K08 · FY2011 · AI · contact PI
Mucosal Immune Checkpoints in Chronic Bacterial Cystitis$118,621
K08 · FY2010 · AI · contact PI
Mucosal Immune Checkpoints in Chronic Bacterial Cystitis$115,952
K08 · FY2009 · AI · contact PI